Choosing the right registration pathway for the China drug master file: an essential analysis of options


Building upon the foundational insights presented in the first article of our China series, this subsequent piece delves deeper into the intricacies of China’s drug master file (DMF) registration pathways. Focused on active pharmaceutical ingredients (API), excipient and packaging material products, this article provides a crucial analysis of these pathway options.

By illuminating the advantages and considerations inherent in each of the options, this article aims to empower DMF applicants with the knowledge necessary to strategically optimise their registration processes within the dynamic regulatory environment of China. This comprehensive exploration serves as a valuable resource for industry professionals seeking to navigate and excel in DMF registration in China.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member